The Ensuring Patient Access and Effective Drug Enforcement Act was a bipartisan, commonsense advance to enhance enforcement efforts and fight the opioid epidemic.
At its core, the law supported higher coordination in between the Drug Enforcement Administration and drug makers and suppliers, drug stores and physicians. In no chance does it lessen DEA’s enforcement tools.
The legislation outgrew a concern that the DEA’s hit-and-miss regulative technique had produced an environment of unpredictability and, more crucial, was starting to affect patient access to needed treatments.
Before enactment of the legislation, DEA released instant suspension orders based upon its own meaning of what makes up a public health hazard– a meaning that was possibly ever altering. The outcome was a large gray area topic to individual decisions that was detrimental in controlling among the most complicated, essential markets in the nation.
To resolve this, the law now supplies a simple meaning for “impending threat to the public health.” While the law develops higher clearness, DEA also stays completely empowered to take quick action when a “considerable possibility of an instant risk that death, major physical damage, or abuse of an illegal drug will take place.”.
Sen. Orrin Hatch, among the authors of the legislation, on the Senate flooring today completely exposed TheWashington Post/60 Minutes reporting and explained that the language of “impending risk” came straight from the DEA and Department of Justice lawyers.
Even more, the legislation entered the result in April 2016– well after the opioid epidemic took hold. Based upon this timeline, the law had no bearing on any enforcement downturn that took place in previous years, as declared by the reporting.
The law was worked out transparently with DOJ, DEA, and Congress. Eventually, it passed all and was signed into law by President Obama with the complete assistance of everybody around the table.